ClinicalTrials.gg
CompletedNCT04065711Updated Sep 22, 2021

Study of the Soliton Rapid Acoustic Pulse (RAP) Device for the Treatment of Cellulite

An interventional study of Soliton's Rapid Acoustic Pulse (RAP) in Cellulite, sponsored by Soliton. Completed at 4 sites in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-22.

Sponsored by Soliton · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2021, 5 years 3 months ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

To evaluate the safety, and efficacy of Soliton's Rapid Acoustic Pulse (RAP) device for the temporary improvement in the appearance of cellulite.

Read the detailed description

Multi-site clinical study to evaluate the safety, efficacy and tolerability of Soliton's Rapid Acoustic Pulse (RAP) device fo the temporary improvement in the appearance of cellulite.

02

Conditions studied

  • Cellulite

Browse trials for

03

In context

Cellulite

71 studies on the registry are indexed under Cellulite; 3 are open to participants now.

This study's enrollment of 67 is above the median of 34 across 65 interventional studies indexed under Cellulite.

Browse Cellulite studies →

Lead sponsor

Soliton is the lead sponsor of 7 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female ages 18-50 years
  • Seeking treatment of cellulite in the thigh and/or buttock areas
  • Area of severe cellulite on the thigh and/or buttock with an average simplified Cellulite Severity Scale at Baseline ≥ 4.0 (Table 2)
  • Having at least one dimple, or ridge-depression, in the treatment area, with a depth of approximately 5 mm or greater.
  • Stable weight nominally +/- 5% for at least the past 6 months.
  • (B.M.I.) is ≤ 30
  • Participant will not have had invasive or energy based cellulite treatments (liposuction, subcision, RF, laser, ESWT, etc.) for the prior 12 months.
  • Participant will not have used topical based cellulite treatments for prior 6 months and will not use during the trial.
  • Will not undergo any other cellulite treatments for a period of 12 months following RAP treatment.
  • Participant is willing to participate in study and adhere to follow-up schedule
  • Participant is able to read and comprehend English
  • Participant has completed the Form

Exclusion criteria

Exclusion Criteria:

  • Participant is unwilling to have research photos taken of treatment areas in the presence of Sponsor's researchers.
  • Participant is unwilling to have RAP treatment provided in the presence of Sponsor's researchers.
  • Participant is pregnant or planning to become pregnant during the duration of the study.
  • Has atrophic scars, or has a history of atrophic scars or keloids.
  • Tattoo or former tattoo at or near treatment area.
  • Metal or plastic implants in the area of the treatment (vascular stent, or implants in the hips, knees, etc.).
  • Active electronic implants such as pacemakers, defibrillators, cochlear implants, nerve/brain stimulators, drug pump, etc.
  • Medical disorder that would hinder the wound healing or immune response (no blood disorder, inflammatory disease, etc.).
  • History of coagulopathy(ies) and/or on anticoagulant medication.
  • Skin disorders (skin infections or rashes, extensive scarring, psoriasis, etc.) in the treatment area.
  • Current smoker.
  • Any surgical procedure in the prior 3 months, or planned during the duration of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    RAP Treatment

    Each treatment area will receive 30-40 minutes (30-40 individual doses) of RAP treatment.

    Device: Soliton's Rapid Acoustic Pulse (RAP)

Interventions

  • DeviceSoliton's Rapid Acoustic Pulse (RAP)

    Treatment for the temporary improvement in the appearance of cellulite.

06

What researchers measure

Primary outcomes

  1. Procedure Safety- All treated participants are free from unexpected adverse events

    The primary objective is to demonstrate freedom from unexpected adverse events (UAEs) and serious adverse events (SAEs) directly attributable to the RAP device or treatment.

    Time frame: 12 weeks

Secondary outcomes

  1. RAP treatment effectiveness

    To demonstrate temporary improvement in the appearance of cellulite as determined by blinded independent physician assessment (IPA) correctly identifying the 12-week post-treatment photographs from randomly placed side-by-side comparison of before and after photographs.

    Time frame: 12 weeks, 26 weeks and 52 weeks

07

Study locations

4 sites
  • Clear Dermatology and Aesthetics Center Investigate MD
    Scottsdale, Arizona 85255, United States
  • Chicago Cosmetic Surgery & Dermatology
    Chicago, Illinois 60654, United States
  • Capital Laser and Skin Care
    Chevy Chase, Maryland 20815, United States
  • SkinCare Physicians
    Chestnut Hill, Massachusetts 02467, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jul 2021, 24 months.

Of 20 interventional studies with no phase under Cellulite, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2019
First posted
Aug 22, 2019
StartActual
Jul 20, 2019
Primary completionActual
Jul 20, 2021
CompletionActual
Aug 26, 2021
Last update
Sep 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04065711
Lead sponsor
Soliton
Responsible party
Sponsor
First posted
Aug 22, 2019
Start date
Jul 20, 2019
Primary completion
Jul 20, 2021
Completion
Aug 26, 2021
Last update
Sep 22, 2021

Study contacts

Christopher Capelli, MD
study director · Soliton, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion